Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →A patent landscape of cell-free expression of membrane proteins: 170 records from 2015–2026, filing trends, IPC composition, leading assignees and where claim space remains open.
Filing growth = 2021 (2 records) → 2024 (2); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 170 records in scope (CR5), not the ranked leaders only.
This landscape tracks 170 patent records published between 2015 and 2026 that combine cell-free protein synthesis or in vitro translation methods with membrane or transmembrane protein targets, using liposomes, nanodiscs, detergents or reconstituted membranes as the expression environment. The scope is narrow by design: it isolates the intersection of cell-free biology and membrane biochemistry rather than either field alone, so a general cell-free expression patent that never touches membrane proteins falls outside it, and a membrane protein patent that relies on cellular expression does too.
Coverage runs through a data cut-off of 2026-08-31, and because publication typically lags filing by roughly 18 months, the most recent one to two years understate real filing activity. Records are drawn from national and PCT filings, and the assignee ranking reflects 170 families across 89 ranked companies and institutions — the full set the data endpoint returns, not a top-50 or top-100 cut.
Pick a task. Every answer cites the patents behind it.
Two views of the same 170-record dataset: how filing activity has moved year over year, and which IPC subclasses carry the claim language.
Filings peaked at 10 in 2017 and have since settled into a low, flat pattern — 2021 and 2024 both recorded 2 filings, a 0% change over that three-year span. Treat the final one to two years on the chart as incomplete rather than as evidence of decline, since publication lag has not yet caught up with recent filing activity.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
C12N (microorganisms and genetic engineering) appears on 55.3% of the 170 records and C07K (peptides and proteins) on 44.1%, reflecting that most claims center on the expression system and the protein construct itself. A61K (medicinal preparations) reaches 41.8%, showing a strong therapeutic-development orientation, while C08G (condensation polymers), at 4.7%, marks the thinnest-claimed branch — a synthetic-membrane-material angle that few filers have committed to.
Shares are the percentage of the 170 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about cell free expression of membrane proteins patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe filing describes a T-cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein, along with peptides, polypeptides and antibodies derived from it. Claimed elements include peptides and antibodies capable of inhibiting T-cell stimulation through the TIRC7 membrane protein, vectors carrying the relevant polynucleotides, host cells transformed with those vectors, and pharmaceutical and diagnostic compositions built around them.Filed by Brigham and Women's Hospital, this 2003 filing predates the cell-free expression methods now common in the field but still anchors claim territory around the TIRC7 membrane protein target and its antibody derivatives.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2013120629A1 | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal … | 308 |
| 2 | WO2019157529A1 | Methods characterizing multiple analytes from individual cells or cell populations | 282 |
| 3 | WO2013120628A1 | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal … | 236 |
| 4 | US20150057340A1 | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal … | 184 |
| 5 | WO2013120497A1 | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal … | 166 |
| 6 | WO2013120499A1 | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal… | 137 |
| 7 | WO1999011782A1 | T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof | 55 |
| 8 | WO2008106660A2 | Isolated phospholipid-protein particles | 50 |
| 9 | US20170056529A1 | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal … | 43 |
| 10 | US10166283B2 | Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal … | 39 |
Citation counts reflect an older cohort of records and should be read as a signal of influence within this corpus, not as a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Four read-outs from the same dataset, each pointed at a different practical question.
The leading assignee alone accounts for 42 of the 170 records in scope, and the top five combined reach 65.3% of all filings. That level of concentration means new entrants are more likely to be filing around a small number of dominant claim holders than competing against a diffuse field.
Filings peaked at 10 in 2017 and have not returned to that level since; 2021 and 2024 both sit at 2 filings apiece. This reads as a mature, narrow niche rather than a growth area, though the most recent one to two years are still filling in due to publication lag.
C12N (microorganisms and genetic engineering) and C07K (peptides and proteins) together anchor the bulk of claim language, while C08G (condensation polymers), at just 4.7% of records, marks a comparatively open branch on the materials side of membrane reconstitution.
WIPO (PCT) filings lead at 40, ahead of Europe at 34 and the United States at 26, suggesting many applicants in this space are securing broad international priority before narrowing to specific national phases.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to cell free expression of membrane proteins patent landscape, with the prior art for and against each one.
The dataset points to a concentrated, plateaued field with a narrow set of dominant claim holders. The next steps depend on whether the goal is freedom-to-operate, licensing, or identifying open claim territory.
With 65.3% of records held by five entities, a freedom-to-operate review should start by pulling the granted claims of those five before evaluating the long tail of single- or few-filing entrants.
Explore assignee claims in EurekaC08G-classified records sit at only 4.7% of the dataset, well below C12N or C07K. Anyone with a materials-science angle on membrane reconstitution should check whether that gap reflects unmet technical difficulty or genuine open space.
Run a white-space search in EurekaFiling counts for 2025 and 2026 will rise as pending applications publish. Re-checking the trend in six to twelve months will show whether the 2021–2024 plateau is holding or whether recent activity has picked up.
Track filing trends in EurekaThis dataset counts 170 patent records published between 2015 and 2026 that combine cell-free protein synthesis or in vitro translation methods with membrane protein targets, using liposomes, nanodiscs, detergents or membrane reconstitution. The assignee ranking behind this figure covers 89 companies and institutions across those 170 families. Because publication lags filing by roughly 18 months, the true count for the most recent one to two years will rise as pending applications publish.
One assignee holds 42 of the 170 records in scope, and the top five combined account for 65.3% of all filings, so the field is concentrated rather than evenly spread. The top ten combined reach 92.4% of all records, leaving a comparatively thin long tail of single- or few-filing entrants. A freedom-to-operate review should prioritise the leading handful before working through the remainder.
Filing peaked at 10 records in 2017 and has not returned to that level since; the comparable filings in 2021 and 2024 both sit at 2, a 0% change over that three-year span. That reads as a plateau rather than either growth or decline. The most recent one to two years in any filing trend are always understated because publication lags filing, so a firm read on 2025-2026 activity is not yet possible from this data.
The dataset spans several IPC subclasses, led by C12N (microorganisms and genetic engineering) at 55.3% of the 170 records and C07K (peptides and proteins) at 44.1%. A61K (medicinal preparations) appears on 41.8% of records, pointing to a strong therapeutic orientation, while C08G (condensation polymers) covers only 4.7%, making it the thinnest-claimed branch in the set. These shares add to more than 100% because a single record can carry multiple classifications.
The IPC composition points to C08G-classified condensation-polymer approaches as the most thinly claimed branch at 4.7% of records, compared with over 55% for the leading expression-system classification. Combined with a field where the top five assignees already hold 65.3% of all filings, a new entrant is better served targeting adjacent, under-claimed material or formulation angles than competing directly on core expression-system claims. Any such search should be paired with a full freedom-to-operate check against the leading assignees' granted claims.
Go past this page: query the whole cell free expression of membrane proteins patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page